Increased gross margin and next generation analyzer ready for launch
* Net sales for the period amounted to SEK 42.7 million (41.3), an
increase of 2 %. The second quarter accounted for SEK 20.7 million
(22.8) of this amount.
* The operating profit for the period was SEK 1.8 million (2.8)
and for the second quarter SEK 1.0 million (1.5).
* Earnings per share for the period amounted to SEK 0.06 (0.11).
* Cash and cash equivalents were SEK 9.3 million (16.9) by the end
of the quarter.
* The new analyzer CellaVision® DM1200 was presented in Europe,
and the first orders were taken.
* CellaVision was awarded the SwedenBIO Award for its successes
during 2008.
* CellaVision's Japanese subsidiary received its first order.
* CellaVision qualified for trade on the NASDAQ OMX First North
Premier.
CellaVision in summary
(MSEK) Jan - June 2009 Jan - June 2008 Full year 2008
Net sales 42.7 41.3 100.4
Gross profit 30.9 25.8 63.5
Operating result 1.8 2.8 13.4
Net result 1.4 2.6 13.1
Cash flow -10.3 0.6 3.3
CEO's comment
"CellaVision's products are still receiving a great deal of attention
on our main markets. The hospital market is being increasingly
affected by the global financial crisis and decisions to purchase are
taking longer, which is most apparent on the US market. Having said
that, it is worth noting that we are still showing a positive result
despite a financially unstable world market," says Yvonne Mårtensson,
CEO of CellaVision.
"Our new product, the CellaVision DM1200 provides CellaVision with a
wider and stronger range of products, giving us a more competitive
edge. The product was shown in Europe for the first time during this
quarter. The analyzer was very well received and CellaVision has
already taken its first orders from Sysmex in Europe. We are now
waiting for the product to be ready for sale in the end of July, and
the next step will be to obtain the approvals needed to sell the
CellaVision DM1200 on other markets. The development of this product
has demanded large resources during the period, which has contributed
to the negative cash flow."
"Our investments in our own sales organizations in Japan and North
America have resulted in the first Japanese order received from one
of Japan's largest laboratory chains as well as several important
orders in Canada. North America accounted for 54 % during the
period."
For more information please contact:
Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail:
yvonne.martensson@cellavision.com
Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail:
johan.wennerholm@cellavision.com
Download the report by pressing the link below.
